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Coping with uncertainty: Entrepreneurial sensemaking in regenerative medicine 
venturing 
 
 
 
Abstract 
Entrepreneurs face multiple sources and types of uncertainty during venturing activity. 
Converting novel or speculative opportunities into viable commercial businesses requires 
entrepreneurs to address or even leverage uncertainty. This process is especially relevant in 
nascent, knowledge-intensive fields, where success likely hinges on acquisition and 
deployment of unique, specialized knowledge resources. Venture development will be partly 
determined by the sensemaking strategies entrepreneurs employ to cope with irreducible 
uncertainty, especially as they seek critical collaborations. The regenerative medicine (RM) 
sector represents a unique context for studying entrepreneurial sensemaking under high levels 
of uncertainty. We consider how uncertainty in RM venturing affects entrepreneurial 
behavior. Informed by long-form narrative interviews, we propose a sensemaking model 
linking uncertainty, university culture, coping and narratives of venture potential in the RM 
field. This helps explain how participants in the RM sector cope with uncertainty and explore 
knowledge partnerships. Our findings advance theories of entrepreneurial sensemaking and 
the impact on nascent entrepreneurial ecosystems.   
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Coping with uncertainty: Entrepreneurial sensemaking in regenerative medicine 
venturing  
 
1. Introduction 
Perceived environmental uncertainty (PEU) places severe limits on entrepreneurial 
decision-making (Milliken, 1987). When PEU is high, sensemaking helps individuals 
understand and interpret situations, facilitating action (Maitlis and Christianson, 2014). 
Sensemaking provides entrepreneurs and managers with a viable narrative (Weick, 1995) that 
may be communicated to internal and external stakeholders (Cornelissen and Clarke 2010; 
Lounsbury and Glynn 2001). Technology ventures rely on knowledge exchange mechanisms 
and collaboration to develop deep capabilities needed to exploit unfamiliar and complex 
opportunities (George et al, 2008; Powell et al, 1996). 
We study how uncertainty affects entrepreneurial sensemaking through a situational 
analysis of regenerative medicine (RM) venturing activity. The RM sector represents a useful 
context for studying entrepreneurial activity under uncertainty. The science of RM, which 
emphasizes the use of stem cells, is “the process of creating living, functional tissues to repair 
or replace tissue or organ function lost due to age, disease, damage or congenital defects” 
(NIH, 2006). RM presents unique challenges to venturing activity. Extremely high levels of 
irreducible uncertainty have hindered the development of RM venturing, slowing new firm 
formation and growth (Ledford, 2008). We define irreducible uncertainty as uncertainty that 
cannot be reduced by information gathering or analysis, and which reflects an unknown but 
not an unimaginable future (Gloria-Palermo, 1999). 
Scientific knowledge requirements, regulatory complexity and research capital intensity 
has led to a limited number of RM centers of excellence. Scotland (United Kingdom), 
particularly the capitol city Edinburgh, has a long established history of RM research. The 
University of Edinburgh houses The Scottish Centre for Regenerative Medicine (SCRM). 
This is a world-leading RM center, with the advancement of RM research, translation and 
commercialization at the very core of the organization. Yet despite this, venturing activity has 
been slow. This provides a unique opportunity to investigate an ecosystem in its formative 
stages. 
Informed by a pilot survey and long-form narrative interviews, we explore how 
participants make sense of a highly uncertain venturing context. Our research makes three 
contributions to the study of entrepreneurship under uncertainty. First, we highlight the 
development of coping strategies during the sensemaking process. We show that RM 
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individuals differ in their perceptions of PEU and in their coping responses. We discuss the 
types of coping strategies and the potential implications for venturing behavior.  
Second, we extend university-industry scholarship by showing an association between 
university entrepreneurial culture and entrepreneurial coping strategies. A substantial body of 
literature exists on the entrepreneurial university (e.g. Etzkowitz, 2000; Etzkowitz, 2003; 
Rothaermel et al, 2007). We extend prior research to propose that coping strategies are 
tightly linked to entrepreneurial culture at the parent institution. Role-identity conflicts and 
entrenched hurdles for commercialization activities are more likely to generate coping 
strategies that hinder collaborative knowledge development.  
Finally, we propose a model of sensemaking under irreducible uncertainty. We link 
uncertainty and parent institutional culture to the development of coping strategies, and 
ultimately the impact of these coping strategies on collaborative knowledge building and 
perceptions of venture development potential. The interpretations generated in this 
sensemaking process have direct and important implications for venture growth strategies and 
resource assembly activities.  
Our study opens new research directions linking entrepreneurial sensemaking to coping 
strategies and collaborative knowledge development when uncertainty cannot be resolved by 
information gathering or analysis. Despite important implications for theories of 
entrepreneurial behavior and venture development, entrepreneurial coping strategies have 
received relatively little attention. We also build upon recent investigations on selective 
revealing as an alternative form of entrepreneurial collaboration under uncertainty (Alexy et 
al, 2013).  
This paper is organized as follows. Section 2 provides an overview of venturing in the 
RM field and the nature of uncertainty. It also explores sensemaking under high levels of 
uncertainty. Methods, data and procedures of this study are discussed in Section 3. We report 
our research findings in Section 4 and discuss results in Section 5. We offer conclusions in 
Section 6. 
 
2. Literature 
Our research seeks to inform theories of entrepreneurial sensemaking under irreducible 
uncertainty and the resulting effects on the development of entrepreneurial ecosystems. 
Focusing on the RM sector presents a useful context for investigating these phenomena. 
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2.1. Venturing in the regenerative medicine field 
RM venturing is difficult and uncertain. The RM industry faces complex political and 
social forces, uncertain regulatory frameworks, unresolved intellectual property (IP) rights 
issues, and untested production and distribution systems (Hogle, 2014). The investment and 
infrastructure requirements of RM commercialization have favored entrepreneurial activities 
with explicit links to university research programs. Commercialization of university-led stem 
cell innovations is likely to be dependent upon cultural norms and institutional contexts 
(Walshok et al, 2014; Zahra and Wright, 2011). The dependency on the larger institution may 
create resource assembly challenges for new technology ventures (Powell et al, 1996). These 
firms must operate with little or no slack in their resource pool, limiting product-market and 
business model exploration and testing (Bock et al, 2012; George, 2005). RM business 
models remain mostly unproven, evolving through a trial-and-error process (Costa and Levie, 
2012; Heirman and Clarysee, 2004; Loch et al, 2008). Uncertain business models and the 
perception of high risk in RM venturing hinders investments by venture capitalists (VCs) and 
pharmaceutical companies. This has created a knowledge and capabilities gap between RM 
innovation and commercialization.  
Knowledge resources are especially important to new ventures (Grant, 1996; Powel et 
al, 1996). Ventures commercializing novel innovations may compensate for resource scarcity 
by accessing social networks to legitimize organizational narratives and access knowledge 
and financial resources (Aldrich and Martinez, 2001; Lounsbury and Glynn, 2001). The 
sophisticated technological requirements of RM, however, increase these firms’ need to 
explore boundary-spanning resource exchange mechanisms in order to become competitive. 
In dynamic and complex industries, collaboration and knowledge exchange enable early 
stage ventures to develop deep and sophisticated capabilities in order to exploit opportunities 
(George et al, 2008). At the same time, technical knowledge increases collaboration costs and 
uncertainty about partner capabilities and intents. The use of selective revealing to reduce the 
perceived risk of disclosure may induce the external firm to become more similar to the focal 
firm with respect to the production of knowledge (Alexy et al, 2013).  
The RM field has suffered from ethical and legal hurdles that have made public or 
broad disclosure costly. When high amounts of uncertainty and controversy surround a novel 
technology, legitimization of this technology becomes essential to resource assembly (Jain 
and George, 2007). Legitimization of novel technologies is possible through ventures 
protecting their technology, widely publicizing their technology and influencing key 
stakeholders (Jain et al, 2009). Entrepreneurs in the field of RM have relatively fewer options 
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for either safely testing legitimizing narratives or exploring collaborative partnerships, 
without risking the loss of protecting IP.   
Venturing in RM will require entrepreneurs to address high levels of irreducible 
uncertainty. RM entrepreneurs and ventures must rely on risky, costly collaborations and 
networks to access resources, including knowledge, in order to exploit opportunities. The 
processes, however, have not been carefully investigated to understand the drivers of such 
collaboration efforts. As the development of collaboration and knowledge exchange networks 
are likely important to the formation of the broader ecosystem, studying entrepreneurial 
cognition in this context offers a window to much larger scale effects under conditions of 
perceived uncertainty.  
 
2.2. The nature of uncertainty 
Venture success depends on entrepreneurs recognizing and responding to uncertainty 
(McKelvie et al, 2011). Perceived uncertainty is generally classified as state, effect or 
response uncertainty (Milliken, 1987). State uncertainty describes environmental 
unpredictability. Effect uncertainty represents the inability to predict the impact of 
environmental change. Response uncertainty limits the ability to predict consequences of 
choice or action. The appropriate responses to uncertainty lead to growth and firm value 
(Sirmon et al, 2007). Since uncertainty, in contrast to risk, cannot be resolved via data 
gathering or analysis (Knight, 1933), entrepreneurs cannot manage uncertainty. They can 
only be prepared for contingencies and cope with living with the unknown. 
Coping with uncertainty is a three-staged process. It involves primary appraisal in 
which individuals evaluate the threats to themselves. Secondary appraisal considers the 
response options available in order to deal with these threats. Coping with these threats relies 
on implementing the response options available and involves the use of two coping functions: 
a problem-focused coping and an emotion-focused coping (Lazarus and Folkman, 1984). 
During stressful situations individuals will utilize both types of coping functions in 
addressing the particular problem. However, problem-focused coping tends to predominate 
when individuals perceive that they can address the particular situation and emotion-focused 
coping prevails when the situation is less controllable (Folkman and Lazarus, 1980). These 
are fundamentally sensemaking choices. Entrepreneurs make sense of uncertainty by either 
choosing (consciously or unconsciously) to ignore it, or by attempting to solve unsolvable 
problems. 
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2.3. Entrepreneurial sensemaking within high uncertainty environments 
The cognitive processes of entrepreneurs during venture creation warrant careful study 
(Forbes, 1999). Prior research has focused primarily on opportunity recognition and decision-
making under uncertainty (Haynie et al, 2010; McMullen and Shepherd, 2006). Much 
remains to be investigated, including the unique role of sensemaking, as entrepreneurs 
explore unfamiliar opportunity sets or create entirely new markets (Grégoire et al, 2011). 
Organizational research on sensemaking generally emphasizes how individuals make 
sense of ambiguity and uncertainty within a broader, stable context (Maitlis, 2005; Maitlis 
and Christianson, 2014; Weick, 1995; Weick et al, 2005). Even as scholars examine response 
to chronic pressure or acute crises (Cornelissen, 2012; Maitlis and Sonenshein, 2010; Weick, 
1988; Weick, 1993; Weick and Sutcliffe, 2003), the backdrop of a larger institutional 
framework provides the overarching norms and expectations of an established organization or 
industry. Not surprisingly, research has carefully examined how such institutional contexts 
influence sensemaking processes (Nigam and Ocasio, 2010).  
Sensemaking is critical during venture formation, converting the unfamiliar or 
unknown to the familiar and understandable (Cornelissen and Clarke, 2010; Hill and 
Levenhagen, 1995). Entrepreneurs observe and interpret data associated with “known 
unknowns.” Deriving choice sets from vague and limited data rationalizes environmental 
uncertainties, enabling action (Maitlis, 2005). Entrepreneurs use sensemaking to construct 
stories that legitimize novel ideas (Lounsbury and Glynn, 2001; Martens et al, 2007) and 
generate metaphors to communicate complex or strange innovations (Cornelissen and Clarke, 
2010). Entrepreneurs “give sense” to uncertain exogenous contexts to construct new markets 
(Santos and Eisenhardt, 2009) and find meaning in the wake of failure (Cardon et al, 2011).  
Prior knowledge is particularly valuable in making sense of environmental uncertainty. 
Entrepreneurs are likely to rely on their prior knowledge as a cognitive resource, which can 
allow them to recognize opportunities through identifying structural parallels between new 
information and a relevant context (Grégoire et al, 2010). Prior knowledge, along with 
learning approaches, has also been shown to be important in entrepreneurial intent to develop 
and pursue opportunities (Dimov, 2007).  
The underlying mechanisms that activate, influence and enable sensemaking are far less 
well understood. Only recent research has explored the specific cognitive patterns that 
connect the search for meaning to entrepreneurial behavior. Byrne and Shepherd (2013) 
found entrepreneurs engaging in coping strategies in order to make sense of business failure.  
In particular, they found that entrepreneurs with more effective cognitive processing of 
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business failure reported higher levels of emotion-focused coping. Yet, the role of affect-
based patterns in sensemaking are not well-studied in the entrepreneurial literature (Maitlis et 
al, 2013). 
Despite a growing body of research on sensemaking, particularly its importance in the 
study of organizations, research remains fragmented (Maitlis and Christianson, 2014; 
Sandberg and Tsoukas, 2015). A key purpose of our study is to extend prior research on 
patterns of sensemaking cognition, especially when PEU is high. We have very little 
information on how entrepreneurs make sense of the venturing process under conditions of 
irreducible uncertainty. We expect that institutional factors are likely to shape individual 
sensemaking (Nigam and Ocasio, 2010; Weber and Glynn, 2006), but we do not know how 
these effects will present when the new venture is relatively distinct from the prior 
institutional context. We also want to understand how sensemaking influences 
entrepreneurial perception of critical functions to the development of the organization, 
including knowledge collaboration. 
 
3. Data and Methods  
 
3.1. Study context: uncertainty in the RM industry 
The United Kingdom (UK) occupies a world leading position in RM research, with 
stem cell academic centers of excellence located in Edinburgh, Cambridge, London, Oxford 
and Newcastle.  
The UK government is encouraging RM translation in a number of ways. It has 
invested in RM infrastructure to help firms and healthcare providers exploit the long-term 
clinical and economic benefits arising from stem cell research (Taking Stock of Regenerative 
Medicine in the UK, 2011). The governmental funded Technology Strategy Board (TSB) 
agency has established the Cell Therapy Catapult (CT Catapult). This is charged with 
ensuring that the UK becomes a global leader in the development, delivery and 
commercialization of RM. Between 2013-2018, the UK government has allocated £70m of 
core funding to CT Catapult (BIA, 2013). The TSB, in conjunction with the Medical Research 
Council (MRC), has also established a Biomedical Catalyst Translational Funding 
Programme, which offers funding to SMEs and academics. Furthermore, the TSB has 
established knowledge transfer networks (KTN). The Health KTN is tasked with accelerating 
innovation and technology exploitation through knowledge exchange mechanisms. 
Moreover, the TSB also offers various individual funding programs to support SMEs and 
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academics in developing solutions for particular healthcare issues. Governmental funding 
support has also been utilized in order to form the UK RM platform (UKRMP), which seeks 
to address the technical and scientific challenges facing RM research, and to promote RM 
translation. Additionally, the National Institute for Health Research (NIHR) is supporting RM 
to the sum of £9 million a year. Total UK publicly-funded research in RM exceeded £77 
million in 2012 (Regenerative Medicine Report, 2013).  
For stem cell companies and investors, the UK offers a competitive fiscal environment, 
which includes favorable R&D tax credits, reduced cooperation tax rates and significant non-
dilutive grant funding (BIA, 2013). At present there are 26 active RM companies in the UK, 
which is the second highest in Europe behind Germany (House of Lords Scientific Committee 
Report, 2013).  
Within the UK, Scotland has a long and well-known history in RM, popularized by the 
story of Dolly the sheep. Dolly was the first cloned mammal from an adult somatic stem cell 
(Wilmut et al, 1997). Life Science Scotland, a subsidiary of government-run Scottish 
Enterprise, has focused on encouraging RM collaborations, innovations and translation. 
Within the Scottish life science ecosystem, several organizations support RM collaborations 
and translational activities. These include The National Health Service (NHS) Research 
Scotland, which provides an outlet for multi-center clinical studies, and Health Science 
Scotland, which assists academia and industry collaborations.  
The capital city of Scotland, Edinburgh, is home to The Edinburgh BioQuarter. This is 
a £600 million joint venture between Scottish Enterprise, The University of Edinburgh and 
NHS Scotland. The Edinburgh BioQuarter is designed to encourage commercialization at the 
university-industry boundary. Located at The Edinburgh BioQuarter site is The Scottish 
Centre for Regenerative Medicine (SCRM), which provides state-of-the-art research facilities 
to advance stem cell and RM research. Further details relating to the RM ecosystem in 
Scotland and Edinburgh are shown in Table 1. 
--------------------------------- 
Table 1 here 
-------------------------------- 
Despite the RM history and infrastructure in Scotland, venturing in this ecosystem 
remains in a formative stage. The ecosystem is at the forefront of RM research but lags in 
commercialization. This provides an opportunity to witness early-stage ecosystem 
development that would otherwise not be possible in more established RM ecosystems such 
as Boston, San Diego, London or Seoul. 
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3.2. Data 
To explore sensemaking and behavioral processes, we utilize a primarily qualitative 
approach to better develop insights into socially constructed knowledge and events (Locke, 
2001). A small, online pilot survey confirmed the relevance of key constructs, but the 
primary dataset consists of long-form narrative interviews (McCracken, 1988). Information 
about the complete set of qualitative informants is provided in Table 2. 
--------------------------------- 
Table 2 here 
-------------------------------- 
Information on target informants was obtained from The Edinburgh BioQuarter. 
Informants were selected based on direct involvement in the commercialization of RM in one 
of the following four categories: 1) RM entrepreneurs, 2) Academic scientists, 3) RM/life 
science support entities, and 4) RM companies. We excluded for-profit third party support 
firms such as consultancies. We also excluded full-time students, even those with significant 
entrepreneurial intent. This ensured efficient and effective saturation of categories, providing 
sufficient data to account for all aspects of the phenomenon (Morse et al, 2002). Informants 
were not provided detailed information about the interview to prevent prejudicial preparation 
of information or materials. 
 
3.2.1. Long-form narrative interviews 
The lead author conducted face-to-face, long-form narrative interviews with informants 
between November 2012 and September 2013. Interviews were conducted in private facilities 
to prevent interruptions and ensure confidentiality. Informants were asked to “tell the story of 
their participation in the commercialization of regenerative medicine innovation.” Narrative 
approaches are particularly useful for theory building in entrepreneurship (Fletcher, 2007; 
Larty and Hamilton, 2011). Informants were given complete freedom to recount their 
narrative without interruption and with limited or no further direction. This minimizes 
investigator bias, increases informant comfort and encourages informants to recount their 
own story in their own words and focus on self-identified areas of interest. Legal and ethical 
controversies associated with RM require an especially sensitive approach to the collection of 
qualitative data. The open-ended, non-directed narrative approach helps to reduce staged 
responses and social desirability bias (Podsakoff et al, 2003). Informants were encouraged to 
talk until they felt that they had reached a self-determined conclusion. Following the 
informant-determined end of the main narrative, some informants were prompted to provide 
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additional details on key areas of interest. Field notes were generated during and immediately 
after each interview to provide in situ interpretation to complement transcript coding. The 
duration of the interviews ranged from 16 minutes to 111 minutes, with the average length 
being approximately 60 minutes. The final dataset includes 23 long-form narratives, equating 
to 151, 192 words of textual data. 
 
3.2.2. Online pilot survey 
A small-scale, online pilot survey was utilized to confirm the relevance of key 
constructs and frame the coding of the narrative interviews. The survey was designed to elicit 
data on informant’s perceptions of RM venturing. Survey questions included both closed and 
open-ended questions on facilitative and inhibitive factors to RM venturing activity. Question 
types and order were carefully considered to reduce common method biases (Podsakoff et al, 
2003). The survey was pre-tested by administration to an RM industry expert and a RM 
academic scientist to ensure clarity of design and relevance of the questions (Fowler, 2009). 
Survey informants were selected from the RM informant target list and e-mailed regarding 
their participation. We invited 26 individuals to participate in the survey and received 15 
responses, which represents a 58% success rate. Referrals by first-wave respondents to 
additional industry participants generated 7 additional responses. Therefore, a total of 22 
responses were utilized in the pilot survey analysis. 
 
3.3. Procedures 
Analysis of the RM venturing interview narratives was informed by grounded theory 
(Strauss and Corbin, 1990). The results of the pilot survey were used solely to inform and 
validate the qualitative coding process. 1st order codes were generated via open-ended coding 
of the transcripts and triangulated against the results of the pilot survey to identify overlap 
and gaps. 2nd order groupings of the 1st order codes were identified via a cycle of inductive 
and deductive reasoning. Finally, the 2nd order groupings were organized into aggregate 
theoretical dimensions based on reviews of the transcripts and the broader narratives 
described by the informants. All coding was performed using NVivo software. 
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4. Findings 
We first present the findings of the online pilot survey and then the findings from the 
narrative interviews. 
 
4.1. Online pilot survey findings 
As the pilot survey data was used solely to inform the qualitative interview coding, we 
report only simple descriptive statistics. Key findings from the pilot survey are presented in 
Table 3. We note key summary findings that informed the qualitative analysis. First, most 
respondents agreed that RM venturing is challenging due to entrepreneurial resource 
constraints. The majority of respondents suggested that collaborations with universities and 
national-level funders, government entities or national healthcare providers are required to 
overcome these deficiencies. Most agreed that collaborations enabled knowledge exchange, 
access to resources and the development of valuable organizational capabilities. There was 
also agreement that unrealistic commercialization timeframes have been set for RM 
commercialization. Respondents further noted that commercialization was inhibited by 
uncertainties surrounding RM regulation, manufacturing, distribution and scale-up. Despite 
these challenges, most respondents disagreed that RM collaborations were difficult to 
manage. Most disagreed that collaborations with large pharmaceutical firms were required 
for RM commercialization. Respondents were split on whether VC funding was reasonably 
accessible for RM commercialization or whether collaborations were costly and failed to 
deliver. 
The results of the pilot survey clearly confirm some of the challenges of RM venturing, 
but provide first indications of the sensemaking mechanisms that entrepreneurs use to justify 
continued venturing activity. We used these results to inform our qualitative coding 
procedure, as we were particularly interested in the potential for cognitive and sensemaking 
processes. 
--------------------------------- 
Table 3 here 
-------------------------------- 
 
4.2. Narrative interview findings 
The results of the interview coding are presented in Table 4, utilizing a multi-level data 
structure (Walsh and Bartunek, 2011). The first column of the table shows the prevalence (%) 
of 1st order codes within the total (T) 23 interviews. The table also highlights the prevalence 
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(%) of 1st order codes for each informant category, which includes interviews with 6 
entrepreneurs (E), interviews with 3 academics (A), interviews with 12 support entities (SE) 
and interviews with 2 RM companies (RC). 
--------------------------------- 
Table 4 here 
-------------------------------- 
We review the theoretical dimensions revealed by the data and provide illustrative 
examples of 1st and 2nd order codes to highlight findings, relevance and significance. 
 
Perceived environmental uncertainty (PEU). Our data shows high levels of PEU 
surrounding RM venturing. Informants consistently reported high levels of funding 
uncertainties: “Yeah, if you can imagine taking a drug to market, only large pharmaceutical 
companies can really afford to do that…you need GMP manufacturing, you need clinical 
trials, you need safety assays…it’s a very expensive deal. In Scotland we don't have that level 
and the amount of money required.” (Informant #13) 
RM venturing requires bridging this funding gap between stem cell innovations and 
translation. Achieving this is highly uncertain, since RM commercialization activities 
generally exceed investor timeframes and investment limits. High levels of uncertainty also 
surround manufacturing, scale-up and distribution: “…so you have all sorts of problems as to 
how you scale out and manufacture…” (Informant #2) 
RM ventures also face high levels of regulatory uncertainty, especially unresolved IP 
rights issues: “Not only is the regulatory path as expensive as a pharmaceutical with a 
potentially smaller market, it’s also got a huge amount of uncertainty.” (Informant #10) 
Legislative changes regarding the use of human embryonic stem cells (hESCs) has resulted in 
the shift to induced pluripotent stem cells (iPSC) but has required ventures to adapt their 
business model as a consequence. iPSC are seen as more ethically acceptable, but ethical 
uncertainties still surround the RM sector. Furthermore, scientific shifts are likely because 
stem cell science is still in its infancy.  
Many of the uncertainties discussed within the dataset are consistent with previous 
research (Plagnol et al, 2009). Some ventures are not fully committing to this sector, 
deploying limited resources until uncertainty (and risk) is reduced. Therefore, if the sector is 
to see advancements in RM venturing, these uncertainties must be addressed. To achieve this, 
RM ventures are engaging in collaborations, legitimacy building and knowledge exchange 
mechanisms. 
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University entrepreneurial culture. University academic scientists may be expected 
to participate in commercialization activities. This requires the inventing entrepreneur to 
modify their role-identity, shifting from a scientific orientation to a more market-driven 
approach (George and Bock, 2008; Jain et al, 2009). However, this often creates conflicting 
pressures as academics are measured on research papers and grants, not commercialization 
outcomes: “…there’s a tension here isn’t there? Academics are judged by their papers and 
their grants…Spinouts take a lot of time and a huge amount of work…group leaders find that 
extremely difficult because that’s time that they’re not doing their academic work and 
ultimately they will be judged with the current metrics much more on their academic work 
then they will on their commercialization work.” (Informant #9) This tension could impact 
their motivation for commercialization (Etzkowitz, 1998; Ndonzuau et al, 2002).  
Technology transfer offices (TTOs) play an important role in encouraging an 
entrepreneurial culture for academics (Lerner, 2005). The business development capabilities 
of TTO staff can also influence commercialization (Lockett and Wright, 2005; Thursby and 
Kemp, 2002). Some staff may lack the technical and entrepreneurial understanding that is 
required to commercialize stem cell science (Lockett et al, 2005): “I guess again that comes 
down to their tech transfer department to do that. Again, will they necessarily understand? I 
don't think so?” (Informant #1) RM venturing will, therefore, ultimately depend on 
universities deinstitutionalizing their traditional academic culture and adopting a more 
commercially oriented and entrepreneurial one (Dacin et al, 2002; Scott, 2001).  
 
Coping strategies. In order to address high levels of PEU, entrepreneurs or ventures 
will be required to engage in coping strategies (Milliken, 1987). Our findings show 
entrepreneurs and ventures engaging in collaborations and legitimacy building, in order to 
address the high levels of PEU.  
The majority of collaborations are taking place for resource assembly purposes: “…so 
we have access to the cell lines, or at least some of them, from [company name]. That’s a 
collaboration” (Informant #3), and improving particular processes: “…the idea is that we 
can work with them and take some of the processes and tune them up for proper 
manufacturing.” (Informant #15) Collaborations also provide access to funding and can build 
the legitimacy of a particular venture. Collaborations with industry and academia appear to 
be the most dominant types of collaboration within the dataset. Collaborations with the NHS 
are also vitally important for RM venturing, as they enable access to clinicians. However, 
gaining access to the NHS and forming a collaborative partnership is currently challenging: 
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“Access to the NHS is very challenging in Scotland…it’s just something that's not happened 
in Scotland.” (Informant #11) Collaborations involving support entities provide ventures with 
access to executives with expertise in new venture development. They also facilitate in 
connecting ventures with investment communities. However, despite the benefits of 
collaborations, costs associated with collaborations were evident.  
In addition to the role of collaboration in addressing the high levels of PEU, uncertainty 
reduction is also possible as a consequence of legitimacy building. Entrepreneurial stories 
were evident within the dataset as a means of legitimacy building and serving to reduce 
uncertainty: “…we had been talking to him, and talking to him, and talking to him. And he 
didn't, at first, believe that our technology did what it said it did because it is a paradigm 
shift for stem cell technology…and we get a lot of people who don’t believe it, although less 
and less. We are able to show people stuff now that makes them realize that’s it’s the real 
deal…” (Informant #2) Protection of stem cell research, publicizing RM technology through 
raising awareness, and influencing key stakeholders was also evident within the dataset as a 
means of legitimization. 
 
Collaborative knowledge. Coping strategies can enable access to knowledge for 
venture formation and growth. Our findings highlight the exchange of knowledge and 
communication between the various actors operating within the RM sector. Knowledge is 
accessed through collaborations: “I'm working with [name of collaborator] and we are 
developing techniques which hopefully will have commercial applications in the future. So 
it’s kind of using my communication skills and knowledge of embryology and his knowledge 
of transgenics and how that works.” (Informant #4)  
Networks are also important for knowledge access: “…we got them to meet some 
companies through our network…to find out what they're doing, swap information, so that 
kind of activity, I mean, knowledge transfer, it’s community building, access to funding and 
access to partners for collaboration would be the strap line.” (Informant #12) Knowledge 
access is especially valuable because it can enable capability development: “…we had a 
knowledge transfer partnership with the university… and really that was used to sort of 
develop our capability in creating cell lines that basically took on the form of hepatocytes.” 
(Informant #7) However, informants did discuss the difficulties in exchanging knowledge 
due to the language differences between the various actors within the sector and due to the 
tacitness of RM knowledge.  
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Social networks have been suggested to be an important mechanism for the assembly of 
resources and in the creation and exchange of knowledge (Aldrich and Martinez, 2001; 
Ardichvili et al, 2002). Within the RM sector there are several life science communities that 
have been established, with the aim of ensuring successful RM venturing. For example, The 
Health KTN organizes events and workshops where RM industry actors can meet in order to 
share ideas and gain access to potential collaborators. This network also acts as a facilitator 
for the identification of new sources of funding. 
 
Narratives of venture potential. Accessing resources, including knowledge, through 
collaborations and networks can enable RM ventures to form and grow. During this venture 
development period, ventures may continue to engage in coping strategies resulting in 
additional collaborative knowledge. However, RM venture development is challenged due to 
a lack of slack resources, especially financial resources. Governmental funding appears to be 
available for basic scientific RM research and to progress RM research to phase I/II studies. 
However, access to funding for clinical stage research and to deliver this research to the 
market is currently challenging: “…because at the moment people in regenerative medicine 
talk about a funding gap and you'll hear this from many people, but preclinical stuff...is 
great, it’s all academic. You then sort of do proof of concept stuff which is fundable because 
it’s fairly cheap, but then there's this clinical development which is extremely expensive and 
small companies can't afford it, universities certainly can't afford it.” (Informant #3) At 
present, entrepreneurs and early stage RM ventures are required to match governmental 
funding with their existing financial resources, which is difficult.  
Business model evolution through trial-and-error was exemplified within the dataset. 
When complexity and uncertainty are high, ventures may run multiple parallel business 
models and select the best performing one (Loch et al, 2008): “The other part to it which 
actually never really materialized…we also thought there was the opportunity of people 
actually utilizing our facilities to undertake that work. In reality that bluntly didn't happen for 
whatever reasons…what we did, to some extent, is move away from a company that was 
almost a service company to one that would eventually have product or products based on IP 
in one form or another, whether patented or not, that we could then market.” (Informant #7) 
Informants also discussed uncertainty surrounding their own business model, in some 
cases discussing business model failure or changes to their current business model due to a 
lack of market demand. This highlights that RM business models cannot be predicted ex ante. 
Entrepreneurs discussed their desire to become players in the RM therapeutics market, but 
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due to the high uncertainties and costs of being involved in this market, all were prevented 
from operating in this space. Therefore, it appears from the dataset that RM ventures focusing 
on tools or diagnostics may have a clearer path to a viable business model than those 
focusing on therapeutics. This is because the financial resources required for 
commercialization of tools or diagnostics is significantly lower than the financial resources 
required to commercialize therapeutics. However, given the current uncertainty within the 
RM sector, young RM tools or diagnostic ventures are likely to face downstream 
uncertainties such as reimbursement uncertainties. 
University-led RM venturing has the potential to result in significant economic gains. 
However, it should not be forgotten that failure is an unavoidable aspect of any 
entrepreneurial venture and even if universities are successful in transferring their 
technology, they should not always expect the economic gains to accrue to their local area 
(Miner et al, 2001). Informants, especially RM support entities, were concerned with RM 
venturing positively impacting the local economic environment. However, there was some 
concern as to whether the local environment could retain this innovation.  
Despite the high uncertainty surrounding RM venturing, suggestions by informants for 
the trajectory of the market were forthcoming. Informants also discussed the timeframes 
involved for RM scientific progression and widespread venturing. The expected timeframes 
for taking RM science to market differs amongst the actors operating within the sector. VCs, 
SMEs and the UK government do not understand the timeframes involved in taking RM 
science to market, according to entrepreneurs and RM support entities. VCs, SMEs and the 
UK government expect a much quicker return on investment and as a consequence, this has 
serious implications for RM funding and, ultimately, commercialization: “…the time 
horizons of a VC investment just don't fit the time horizons of a development of a 
therapeutic…so the VCs intending to sell it either to other VCs or to trade sale it…I really 
don't like that model, it just doesn't fit.” (Informant #10) 
Our data also highlights differences in how each category of informant addresses 
uncertainty and RM venturing. Findings suggest the relevance of two role-based sensemaking 
lenses, which likely influence or complement the coping strategies in use. We illustrate these 
two role-based lenses in Figure 1.  
Lens 1 consists of the average occurrence of each theoretical dimension for academics 
and support entities. Both place a higher emphasis on university entrepreneurial culture and 
collaborations. The purpose of these collaborations is to progress scientific developments and 
improve current RM processes. 
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In contrast, lens 2 consists of the average occurrence of each theoretical dimension for 
RM entrepreneurs and RM companies. Both approach venturing in a comparable way and 
have similar perceptions of uncertainty, including the significance and effect of uncertainty. 
They also both face the same concerns in relation to funding uncertainties. RM entrepreneurs 
and companies both lack slack resources and place more emphasis on narratives of venture 
potential.  
--------------------------------- 
Figure 1 here 
-------------------------------- 
 
5. Discussion 
The qualitative findings suggest a model of sensemaking under irreducible uncertainty. 
We consider the emergence of different coping strategies that reflect the situational 
understanding of RM ecosystem participants during venturing. Coping strategies affect 
collaborative knowledge development and the resulting narratives of venture formation and 
growth. We consider alternative approaches to collaboration and generate a typology of 
sensemaking under uncertainty. We also discuss the effect of uncertainty on institutional 
culture. 
  
5.1. Sensemaking in RM venturing 
The theoretical dimensions generated by the qualitative analysis reveal a model of 
sensemaking in RM venturing, shown in Figure 2. PEU and institutional entrepreneurial 
culture affect the individual’s preferred coping strategy. The chosen coping strategy then 
influences both the generation of venture narratives as well as collaboration efforts. A key 
purpose of venture narrative is the legitimization of the firm’s innovation or business model. 
We therefore expect that the venture narrative and knowledge collaboration efforts interact. 
Our study is not longitudinal, so we are unable to consider how this interaction shapes the 
actual growth, development or success of a given venture. 
--------------------------------- 
Figure 2 here 
-------------------------------- 
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5.2. Coping with high PEU  
By definition, PEU is a subjectively determined assessment of uncertainty. Informants 
described a variety of relevant uncertainties, including funding issues; manufacturing, scale-
up and distribution uncertainties; regulatory uncertainties; scientific uncertainties; ethics; and 
reimbursement uncertainties. These are consistent with prior analysis of the industry (Ledford 
2008). At a fundamental level, PEU describes environmental unpredictability (Buchko, 1994; 
Milliken, 1987). Freel (2005) discusses three separate dimensions of PEU, which involves 
uncertainties related to the firm’s resources/environment, the firm’s industrial/market 
environment and the firm’s economic environment. According to this categorization, funding 
issues would, therefore, belong to the firm’s resources/environment PEU dimension. Thus, 
coping strategies appear to be part of the cognitive mechanism associated with incorporating 
the uncertainty into the organizational development strategy.  
We have shown coping strategies to include collaborations and legitimacy building. 
These depend on culture and uncertainty, and affect collaborative knowledge development 
and the resulting narratives of venture formation and growth. Coping includes problem-
focused and emotion-focused coping. Several forms of problem-focused coping have been 
identified, such as specific interpersonal efforts to alter the stressful situation or the seeking 
of social support (Folkman et al, 1986b). The specific problem-focused coping form 
implemented by entrepreneurs is likely to have differing effects on resource assembly and 
collaborative knowledge development. For example, RM entrepreneurs implementing 
problem-focused coping, in which they seek social support, may find that they are unable to 
assemble resources and develop collaborative knowledge. Seeking social support relies on 
entrepreneurs obtaining external advice, assistance or knowledge. Yet, if support is sought 
from RM individuals who have coping strategies linked to venture failure, resource assembly 
and collaborative knowledge development will be challenged. 
Emotion-focused coping strategies enable entrepreneurs to manage their emotions in 
relation to the uncertainty and are most suited to uncontrollable situations. Therefore, they are 
especially valuable to entrepreneurs and ventures during RM venturing due to the high levels 
of irreducible uncertainty surrounding RM. Several forms of emotion-focused coping 
strategies exist, which can facilitate or inhibit problem-focused coping. These include: denial, 
wishful thinking, distancing, emphasizing the positive, self-blame, tension-reduction and self-
isolation (Folkman et al, 1986a). Again, we can expect resource assembly and collaborative 
knowledge development to proceed differently depending on which form of emotion-focused 
coping is adopted. For example, entrepreneurs relying on wishful thinking may fail to see 
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potential flaws in their business model or RM technology. If they then collaborate for 
resource assembly and knowledge development purposes, homophily effects suggest that the 
collaborating firm will also fail to see the potential flaws. This will have serious 
consequences on venture formation and growth. Therefore, we propose that: 
 
Proposition 1: Under high levels of PEU, coping strategies relying on wishful 
thinking or denial are associated with reduced knowledge collaboration and 
venture narratives that emphasize the venture’s current innovation as the key 
component of a successful business model. 
 
Proposition 2: Under high levels of PEU, coping strategies relying on problem-
solving or exploration are associated with increased knowledge collaboration and 
venture narratives that emphasize addressing a specific market need as the key 
component of a successful business model. 
 
Our findings have confirmed that individuals differ in their perceptions of uncertainty 
(Duncan, 1972) and in their coping responses (Carver et al, 1989). We have reported that 
entrepreneurs rely less on coping strategies for venture development than any of the other 
RM participants in our study. The UK government’s commitment to RM commercialization 
has encouraged a wide range of support entities, which we have shown to rely heavily on 
collaborations as a coping strategy to the high levels of PEU. In some instances, support 
entities are measured on the number of collaborations that they establish. Therefore, we see 
RM support entities actively encouraging RM firms and entrepreneurs to engage in 
collaborations. Yet, our situational analysis reveals that this conflicts with how RM 
entrepreneurs deal with high levels of PEU. Conflicts towards the best commercialization 
pathway may prove to be detrimental to RM venture formation and growth. Irreducible 
uncertainty and variations in the best commercialization path, could lead to the grouping of 
RM informants based on homophily effects. This may have serious implications for venture 
outcome, as groups will either randomly all succeed or fail based on whether their 
interpretation of the best commercialization path was accurate or not (Miner et al, 1996). 
Thus, support entities that are at odds with entrepreneurs’ coping strategies are unlikely to 
provide useful support, unless they are in fact converting entrepreneurs to coping strategies 
that are linked more to success.  
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5.3. Collaboration under irreducible uncertainty 
Our findings indicate that entrepreneurs rely on coping strategies less than any other 
category. Findings also indicate that costs exist during collaborations and unwilling 
collaborators. In addition, given the high levels of PEU, high partner uncertainty is expected. 
Under conditions of high collaboration costs, unwilling collaborators and high partner 
uncertainty, it is possible that RM entrepreneurs and new ventures rely on selective revealing 
as an alternative strategic mechanism to known collaboration mechanisms (Alexy et al, 
2103). However, the use of selective revealing strategies in RM venturing may be 
problematic. If the focal firm is associated with coping strategies that are linked to venture 
failure, then we propose that collaborative networks of ignorance will be created, since the 
external firm also becomes associated with coping strategies linked to venture failure. This 
will have serious implications for the development of collaborative knowledge, since 
opportunity recognition depends on individuals mentally comparing new information with 
prior knowledge through a cognitive process of structural alignment (Grégoire et al, 2010). 
Therefore, we expect that: 
Proposition 3: Coping strategies, which rely on selective revealing during 
collaboration, are associated with partnering that favors firms with similar business 
models as the focal firm. 
 
5.4. Institutional culture  
RM venturing is driven by university-led stem cell research. The embedded 
institutional culture and processes at the university and TTO are likely to have an imprinting 
effect on the structure and characteristics of RM ventures which emanate from the university 
(Kimberly, 1975; Stinchcombe, 1965). At founding, new ventures are determined by the 
specific technological, economic, political and cultural resources that are available to them 
(Johnson, 2007). To ensure their survival and growth, they must follow strategies that are 
rewarded by their external environment (Kriauciunas and Kale, 2006). However, since RM 
ventures operate under extended periods of high levels of uncertainty, it is reasonable to 
suggest that imprinting effects will have unintended outcomes on the survival of young RM 
ventures. Therefore, imprinting effects and the inventing academic-entrepreneur’s prior role-
identity conflicts presents significant challenges to RM venturing. We suggest that:  
Proposition 4: A weak entrepreneurial culture in the parent institution is 
associated with emotion-based coping strategies in its spin-off ventures. 
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Proposition 5: A strong entrepreneurial culture in the parent institution is 
associated with problem-based coping strategies in its spin-off ventures. 
 
5.5. A typology of knowledge collaboration during venturing under high uncertainty 
Combining the role-based lenses with the coping strategies generates a typology of 
sensemaking profiles under uncertainty. The generation of archetypal sensemaking 
approaches to inherently uncertain activities presents a useful tool for entrepreneurs, research 
institutions and policymakers to better understand and potentially influence the evolution of 
an entrepreneurial ecosystem. The typology is shown in Figure 3. 
--------------------------------- 
Figure 3 here 
-------------------------------- 
 
Focused visionaries are participants in the RM ecosystem that have settled on a key 
innovation or business model and plan to see it through regardless of the development of 
alternative innovations or collaborative opportunities. 
Informed observers have similarly determined a relatively set position with regard to 
technology or innovation but are not actively engaged in commercialization. 
Open innovators are individuals engaged in commercialization activity based on a 
primary technology, but are willing to take the risk of collaboration in order to best address a 
given market problem. 
Curious bystanders are not directly involved in commercialization, but have specific 
market problems or industry needs in mind and encourage collaboration for the sake of 
improving the knowledge of the ecosystem as a whole. 
At this time, we have no information on whether ecosystems benefit more from some 
sensemaking profiles than others or whether a specific mix or blend of sensemaking profiles 
is somehow advantageous. We speculate, however, that the level of uncertainty in RM has 
differential effects on individuals, firms and the ecosystem based on sensemaking profiles. 
For example, small ecosystems with relatively limited capital and knowledge resources likely 
reward focused visionaries over open innovators, because they present a more compelling 
narrative to legitimize the venture and its business model. By contrast, curious bystanders 
may be favored in nascent ecosystems because they enable trusted exchange of information 
without extensive and costly contracting requirements. Larger ecosystems still operating 
under significant uncertainty might favor the opposite profiles. Open innovators that 
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emphasize clear market opportunities may ultimately attract more venture capital through 
venturing development activities that emphasize capability development rather than narrow 
technological testing. Similarly, the presence of larger networks of service and financial 
experts may obviate the need for curious bystanders, increasing the relative value of informed 
observers who are aware of untapped innovations that can be tested with minimal resource 
combinations. 
 
5.6. Limitations and directions for future research 
As this is an exploratory study, the sensemaking model should be tested via empirical 
analysis. The inductively derived theories of RM venturing proposed in this study also 
require further testing, refinement and development through further empirical research. The 
dataset is limited primarily to RM venturing informants in Scotland. Similarities in RM 
sector development across western geographies suggest that findings have broader relevance, 
but caution should be exercised beyond early stage RM ecosystems in western economies. 
The dataset over represents RM support entities, therefore, further data collection should 
focus on pre-venture academic entrepreneurs and de novo RM firms. 
Despite these limitations, our results emphasize the importance of research linking 
entrepreneurial cognition and decision-making to venture process, especially under high 
levels of uncertainty. This study opens pathways for future research to reveal the full nature 
of individual and organizational coping responses during opportunity exploitation and under 
high levels of PEU. This may distinguish which coping strategies are linked to success or 
failure in context. From this, we can gain a deeper understanding of coping strategies for the 
assembly of resources, the development of collaborative knowledge and venture outcome. 
Further research in this area also has strong potential to clarify the characteristics of mindsets 
that distinguish academic entrepreneurs from industry entrepreneurs. We also call upon 
further research on the existence and role of selective revealing in RM venturing, particularly 
the drivers and outcomes of this alternative form of collaboration mechanism. This is 
consistent with further research calls from Alexy et al (2013). Finally, our findings also 
encourage further studies to understand the effects of prolonged periods of PEU to 
environmental imprinting and the survival of young RM ventures. 
 
5.7. Policy implications 
 Our study points towards specific policy implications regarding entrepreneurial 
training, ecosystem development, and university entrepreneurial culture. 
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First, many universities have begun offering entrepreneurial training to academics that 
self-select for potential commercialization of their research-based innovations. In knowledge-
intensive fields that operate under high levels of uncertainty, the merits of such training may 
be difficult to measure. In addition to developing traditional business skills, academic 
entrepreneurs report needing to adjust their mindset to operating within an entrepreneurial 
framework (George and Bock, 2008). In fields requiring significant scientific capabilities, 
such as RM, fostering effective academic entrepreneurship may require investing in 
experiential training that directly addresses coping with failure and collaborative knowledge 
development. 
 Second, the role of government in technology ecosystem development requires 
careful consideration. The state has an important role to play in developing novel university-
based technologies whose potential is not yet understood by the business community 
(Etzkowitz, 2003; Mazzucato, 2013). The nature of policies that support ecosystem 
development in nascent technology sectors, however, has not been broadly tested. 
Government support for the growth of an extant, healthy ecosystem is primarily one of 
addressing market failures, such as lack of growth capital and access to markets. In nascent, 
high-uncertainty ecosystems, such as RM, downstream markets may not yet exist, and 
supplemental growth capital would likely go unused or be lost in purely speculative ventures. 
The development of entrepreneurial ecosystems depends on more than environmental 
conditions and institutional policy (Bock and Johnson, 2016).  
 Third, universities must consider entrepreneurial culture as well as commercialization 
policy. Our sensemaking model highlights the role of institutional culture on the development 
of an individual’s preferred coping strategy. Entrepreneurs are adept at finding, adapting and 
exploiting undervalued resources, often through novel, unexpected, or even counter-
institutional processes (Anderson and Warren 2011). The academic entrepreneurs most likely 
to succeed will do so by exploiting supportive policies and side-stepping inhibitive 
restrictions. In other words, universities may need to be less concerned about policies that 
support successful entrepreneurial action, and more concerned about fostering an 
environment and culture that encourages entrepreneurial action in the first place. 
 
6. Conclusions  
We investigated entrepreneurial activity within RM venturing, which is a sector 
characterized by unusually high levels of uncertainty. Our study advances theories of 
sensemaking under irreducible uncertainty by proposing a model linking uncertainty, 
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sensemaking, coping and collaborative knowledge development. Findings present a novel 
picture of organizational coping under high levels of uncertainty. We suggest the need for 
entrepreneurs and new ventures to adopt coping strategies in response to the high levels of 
PEU, which can result in the development of collaborative knowledge and venture 
development. Entrepreneurs and new ventures, which fail to adhere to this, may find 
themselves unable to develop their business model. 
We have also progressed the understanding of university-industry scholarship by 
showing an association between university culture and venture coping strategies. Therefore, 
these findings are especially useful to TTOs. We recommend that universities and TTOs, 
which expect to commercialize their stem cell research, need to consider balancing their 
academic and commercialization culture.  
Our research also has implications to UK government policymakers, who are not only 
charged with ensuring that the UK remains at the forefront of RM research, but also with the 
commercialization of this research.  
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Tables and Figures 
 
 
Table 1. General information about the Scottish regenerative medicine ecosystem 
Population of Scotland 5 295 000 
GDP for Scotland £150 billion 
Capital city of Scotland Edinburgh 
Population of Edinburgh 495 360 
Significant local industries Education, health, finance, insurance, agriculture, tourism 
and whiskey 
VC in region <5 
University of Edinburgh 
(UoE) student population 
30 579 
UoE annual research budget £286 million 
University research income £316 million 
UoE College of Medicine 
faculty  
2594 
Medical research  Estimated £109 million 
UoE TTO activity TTO founded in 1969. 
423 patents filed 2007-2012. 
£3.5 million license/royalty income in 2011. 
160+ active commercial license agreements.  
171 spinout/start-ups since 1969. 
UoE RM patents granted 
between 2009-2011  
9 
UoE RM publicity Dolly the sheep 
Note: All data for 2012-2013 unless otherwise noted. 
Sources: University of Edinburgh and subsidiary School/College websites and Annual 
Report, and Scottish Government websites (including UK Intellectual Property Office). 
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Table 2. Study informant information 
# Informant’s role Category Organization type Location 
1 Director of Operations Support entity Services  Edinburgh 
2 CEO & Founder Entrepreneur Tools/Diagnostics  Glasgow 
3 Business Development RM company Services/Research Edinburgh 
4 CEO & Founder Entrepreneur Services/Research Edinburgh 
5 Academic scientist Academic scientist Research Edinburgh 
6 Economic Development Support entity Services  Edinburgh 
7 CEO Support entity Services Edinburgh 
8 Business Development Support entity Research Edinburgh 
9 Director & Academic Academic scientist Research Edinburgh 
10 CEO & Founder Entrepreneur Cell Therapy UK 
11 Industry Liaison Manager Support entity Services  Glasgow 
12 Technology Manager Support entity Services  UK wide 
13 CEO & Founder Entrepreneur Services/Diagnostics Edinburgh 
14 CSO & Founder Entrepreneur Services Glasgow 
15 CEO  Support entity Services/Research  UK wide 
16 CEO  RM company Tools/Diagnostics UK 
17 Outreach Manager Support entity Services Scotland 
18 International Executive Support entity Services  Scotland 
19 Entrepreneur Entrepreneur Tools/Diagnostics Scotland 
20 CEO Support entity Services/Research Edinburgh 
21 Business Development Head Support entity Services/Research Edinburgh 
22 Academic scientist Academic scientist Research Edinburgh 
23 Business Creation Head Support entity Services/Research Edinburgh 
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Table 3. Summary of pilot survey findings 
Survey statements Key findings – participants’ 
response to statement 
Regenerative medicine commercialization is challenging due to 
the resource constraints faced by organizations 
45% agreed  
32% strongly agreed  
Collaborations are required for regenerative medicine 
commercialization 
45% agreed  
32% strongly agreed 
Governmental funding can be accessed for regenerative medicine 
commercialization 
32% agreed 
23% strongly agreed 
18% disagree 
Unresolved regulatory issues are affecting regenerative medicine 
commercialization 
64% agreed 
Knowledge is exchanged during collaborations 55% agreed 
36% strongly agreed 
Collaboration with hospitals is necessary for regenerative 
medicine commercialization 
41% agreed 
36% strongly agreed 
Unrealistic timeframes are set for regenerative medicine 
commercialization 
41% agreed 
27% strongly agreed 
18% neither agree or disagree 
Collaborations with academic institutions are necessary for 
regenerative medicine commercialization 
45% agreed 
27% strongly agreed 
Venture capital funding can be accessed for regenerative 
medicine commercialization 
32% disagreed 
32% agreed 
23% neither agree or disagree 
Regenerative medicine collaborations often fail to deliver 36% disagree 
32% neither agree or disagree 
23% agree 
Collaborations can provide early stage regenerative medicine 
ventures access to resources 
45% agree 
27% strongly agree 
Collaboration with “big pharma” is necessary for regenerative 
medicine commercialization 
50% disagree 
18% neither agree or disagree 
Manufacturing, distribution and scale-up uncertainties are 
affecting regenerative medicine commercialization 
36% agree 
23% neither agree or disagree 
18% strongly agree 
Regenerative medicine collaborations are difficult to manage 41% disagree 
23% agree 
18% neither agree or disagree 
Regenerative medicine collaborations are costly 27% neither agree or disagree 
27% agree 
18% strongly agree 
Regenerative medicine business models are unknown and 
unproven 
32% strongly agree 
32% don’t know 
Collaborations enable regenerative medicine organizations to 
acquire capabilities 
64% agree 
 
  
Entrepreneurial coping in regenerative medicine 
 34 
Table 4. Data structure 
Prevalence in study sample  
(%)* 
1st Order Codes 2nd Oder Codes Theoretical 
Dimensions 
 T       E       A      SE      RC    
61      83      67     50      50 
74      100    67     58      100 
43      33      67     42      50 
 
39      50      0       42      50 
17      17      33     17      0 
17      33      0       8        50   
13      17      0       17      0    
Risk 
Funding issues 
Mfg, scale-up and distribution 
uncertainty 
Regulatory uncertainty 
Scientific uncertainty 
Ethics 
Reimbursement uncertainty 
Types of 
uncertainty 
Perceived 
environmental 
uncertainty (PEU) 
39      17      33     58      0  
39      17      67     50      0 
30      0        67     42      0 
Academic conflicts 
Academic motivations 
Academic metrics 
Inventing 
entrepreneurs 
University 
entrepreneurial 
culture 35      17      0       58      0   TTO goals and activities TTO goals and 
activities 
91      83      67     100    100 
74      33      100   83      100 
39      17      33     50      50 
35      0        33     50      50 
Collaborations with industry 
Collaborations with academia 
Collaborations with NHS 
Collaborations with support 
entities  
Collaborative 
partners 
Coping strategies 
39      67      67     17      50 
 
30      17      33     25      100 
 
22      0        67     25      0 
 
9        17      33     0        0 
4        17      0       0        0 
Collaboration for sharing of 
resources 
Collaboration for process 
improvement 
Collaboration for funding 
purposes 
Collaboration costs 
Collaboration for legitimacy 
building 
Collaborative 
outcomes 
61      83      67     58      0  Legitimacy building  Legitimacy 
building 
57      67      0       67      50 
70      50      100   75      50 
22      50      33     0        50 
26      17      33     33      0 
Knowledge transfer 
Communication 
Learning 
Language differences 
Resource exchange 
mechanisms 
Collaborative 
knowledge 
57      50      33     75      0 RM and scientific communities  Networks 
87      83      67     92      100 
61      83      33     58      50 
35      0        100   33      50 
Governmental funding 
VC funding 
“Big pharma” funding 
Funding sources 
Narratives of venture 
potential 
65      50      67     75      50 Spinout venture formation Spinout venture 
formation 
61      83      67     58      0 
57      100    33     33      100 
9        33      0       0        0 
Legitimacy building 
Business models 
Integrated business model 
Trial and error 
business models 
78      83      100   75      50 Resources Existing resources 
30      17      33     33      50 
30      0        0       58      0 
Innovation 
Regional investment and 
growth 
Economic 
development 
65      67      67     58      100 
9        17      33     0        0 
Commercialization timeframes 
Potential industry structure 
Future scenarios 
* Does not account for multiple occurrences within a single interview. T = Total sample; E = 
Entrepreneur, A = Academic; SE = Support entity; RC = Regenerative medicine company 
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Figure 1. Revealed significance of uncertainty and venturing 
 
 
 
Figure 2. A model of sensemaking process in RM venturing 
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Figure 3: Sensemaking types in uncertain entrepreneurial ecosystems 
 
 
